Immuneering Launches Registrational Phase 3 Trial for Atebimetinib in Metastatic PDAC
IMRX has more than doubled off its 52-week low of $1.24.
Summary
Immuneering Corp (IMRX) has officially launched its registrational Phase 3 MAPKeeper-301 trial for atebimetinib, targeting first-line metastatic pancreatic ductal adenocarcinoma (PDAC), with the first patient dosing anticipated in mid-2026. This development marks a significant progression from the "upcoming Phase 3 trial" mentioned in the company's 10-Q filing yesterday, confirming the execution of a critical clinical milestone. While the headline also references Q1 financial details (R&D down, G&A up), these aspects were largely covered in yesterday's earnings reports and SEC filings. The launch of a pivotal Phase 3 trial is a major positive catalyst for a clinical-stage biotech company, substantially de-risking its lead asset and moving it closer to potential market approval. Traders will now closely monitor patient enrollment and future data readouts from this key trial.
At the time of this announcement, IMRX was trading at $5.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $333.8M. The 52-week trading range was $1.24 to $10.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.